Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis

  title={Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis},
  author={Jacques Sennesael and Dierik L. Verbeelen and Luc Vanhaelst and Rodolfo Pirola and Silvio R. Bareggi},
  journal={European Journal of Clinical Pharmacology},
SummaryThe pharmacokinetics of a single 2 mg IV dose of chlordesmethyldiazepam has been studied in 11 patients with renal failure on regular haemodialysis and in 11 age-matched healthy controls. The kinetics was also examined after a single 2 mg oral dose in 6 of the 11 renal failure patients.After intravenous administration the kinetics of total chlordesmethyldiazepam in renal patients and controls were the same. The unbound fraction of the drug in renal patients was higher (5.5%) than in… 

Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam

There is a need for caution in the administration of chlordesmethyldiazepam to patients with liver disease, as the elimination half-life was almost twice that in controls and volume of distribution was similar in patients and controls.

Psychotherapeutic Agents in End‐Stage Renal Disease

A number of agents, such as tricyclic antidepressants, were associated with adverse effects that would be imperative to avoid in patients with ESRD, and should be started at low doses and titrated carefully, while monitoring the efficacy and safety of each agent.

Understanding the pharmacokinetics of anxiolytic drugs

A need for a more balanced assessment of the benefits and risks associated with benzodiazepine use, particularly considering pharmacokinetic profile of the drugs to ensure that patients, who would truly benefit from these agents, are not denied appropriate treatment.

Prediction of human systemic, biologically relevant pharmacokinetic (PK) properties using quantitative structure pharmacokinetic relationships (QSPKR) and interspecies pharmacokinetic allometric scaling (PK-AS) approaches for four different pharmacological classes of compounds

This research developed and validated QSPKR models for predicting in-vivo human, systemic biologically relevant PK properties of four, preselected, pharmacological classes of drugs, as well as PK allometric scaling (PK-AS) models for BZD and NMB, using pertinent human and animal systemic PK information from published literature.



Disposition of oxazepam in patients on maintenance hemodialysis

Oxazepam dosage may require downward adjustment for renal failure patients on hemodialysis, and Correction for differences in binding indicates similar distribution of unbound oxazpeam between groups, but reduced clearance of pharmacologically active un bound oxazEPam in renal patients.

Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans

SummarySix healthy, fasting volunteers were given single doses of chlordesmethyldiazepam by 1 mg i. v., or as drops or tablets. Chlordesmethyldiazepam and its metabolite, lorazepam, in multiple

The Pharmacokinetics of Midazolam in Chronic Renal Failure Patients

Because CRF does not alter the distribution, elimination, or clearance of unbound midazolam, changes in the pharmacodynamic profile of midazolate in CRF patients, if they exist, are more likely due to inherent alterations in drug sensitivity than to pharmacokinetic changes.

Alprazolam kinetics in patients with renal insufficiency.

Renal insufficiency has a quantitatively small influence on alprazolam pharmacokinetics, but the difference was not significant.

Effect of renal impairment and hemodialysis on lorazepam kinetics

Since the mean steady‐state concentration depends on drug clearance only, and since clearance is not altered, no dosage adjustment appears necessary for patients with renal disease, and the effect of renal disease on lorazepam kinetics was assessed.

Effects of uremia and hemodialysis on lormetazepam disposition

The results indicate that in uremia lormetazepam biotransformation is not altered, but its glucuronide cumulates by a factor of 5 to 6, while in healthy subjects it is eliminated almost exclusively by the kidneys.

Diazepam kinetics in patients with renal insufficiency or hyperthyroidism.

End-stage renal failure (or its associated drug therapy) alters diazepam protein binding and distribution, but does not significantly change clearance of unbound drug.

Clorazepate dipotassium and diazepam in renal insufficiency: serum concentrations and protein binding of diazepam and desmethyldiazepam.

Clearance of pharmacologically active unbound desmethyldiazepam was reduced in renal failure patients as opposed to controls, and free fraction in serum was greater, and elimination half-life was shorter than in controls.

Renal disease, age, and oxazepam kinetics

Oxzepam was undialyzable; since unbound oxazepam disposition kinetics are not altered, no dosage adjustment for patients is necessary.

Pharmacokinetics of oxazepam following multiple administration in volunteers and patients with chronic renal disease.

The plasma level course and the elimination of oxazepam (Adumbran) via urine were investigated following multiple oral administration in volunteers and patients with chronic renal failure and the non-protein bound oxazEPam in plasma was found to be twice as high in the plasma of patients as that of volunteers.